Aradigm Corporation is a clinical-stage biopharmaceutical company dedicated to developing and commercializing inhaled therapies for the treatment of serious respiratory diseases. Founded in 1994 and headquartered in Hayward, California, the company combines proprietary drug delivery technologies with established compounds to target pulmonary infections and inflammatory conditions. Aradigm’s research and development operations include a state-of-the-art formulation lab in the United Kingdom, positioning the firm to advance inhalation science on a global scale.
The company’s lead program is a liposomal formulation of ciprofloxacin, designed for inhalation to treat chronic lung infections such as non–cystic fibrosis bronchiectasis and cystic fibrosis–associated Pseudomonas aeruginosa. Aradigm’s inhalation platform leverages sustained-release particles that enhance drug retention, reduce dosing frequency and improve patient compliance. In addition to its antibiotic candidates, Aradigm is exploring inhaled anti-inflammatory and mucolytic agents to address underlying disease mechanisms, with multiple clinical trials conducted under both U.S. Food and Drug Administration and European Medicines Agency protocols.
Aradigm serves patients and clinical investigators across North America and Europe, with strategic partnerships aimed at extending its reach into Asia-Pacific markets. The company engages academic medical centers, specialty clinics and contract research organizations to support multi-center studies, regulatory filings and eventual product launch. By focusing on inhalation delivery, Aradigm seeks to provide localized treatment with fewer systemic side effects compared to traditional oral or intravenous therapies.
The company is led by a seasoned management team with extensive experience in drug development, regulatory affairs and commercial strategy for pulmonary products. Supported by a board of directors composed of former senior executives from major pharmaceutical and biotech firms, Aradigm maintains a robust governance framework to guide its clinical programs and partner collaborations. This leadership structure drives the company’s commitment to innovative inhalation solutions for patients with unmet respiratory needs.
AI Generated. May Contain Errors.
